<DOC>
	<DOCNO>NCT01448720</DOCNO>
	<brief_summary>The purpose study explore efficacy paliperidone palmitate administer monthly injection patient acute exacerbation schizophrenia .</brief_summary>
	<brief_title>Treatment Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate</brief_title>
	<detailed_description>This open-label ( patient study staff know identity treatment assign ) study paliperidone palmitate patient acute exacerbation schizophrenia . The total duration study approximately 4 month . Eligible patient without documented history exposure oral risperidone paliperidone extended-release ( ER ) , intramuscular ( IM ) RISPERDAL CONSTA paliperidone palmitate receive oral risperidone 1 mg/day extend release ( ER ) OROS paliperidone 3 mg/day least 3 day first injection study drug ( paliperidone palmitate ) tolerability test . Paliperidone palmitate administer patient intramuscular ( IM ) injection deltoid ( upper arm ) gluteal ( buttock ) muscle .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Be otherwise healthy basis physical examination vital sign Screening ( Baseline ) current diagnosis schizophrenia accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) least 1 year screening longer 5 year ( early diagnose patient ) Have acute exacerbation psychosis define : less 4 week 4 day , PANSS total score 70 120 ( inclusive ) screening ( moderate symptomatology ) , score 4 ( least moderately ill ) screen severity scale CGIS If woman , entry must postmenopausal least 1 year , surgically sterile abstinent . If sexually active , agree practice effective method birth control entry throughout study specify protocol ; If man heterosexually active woman childbearing potential , must agree use doublebarrier method birth control donate sperm study 50 day receive last dose study drug Has evidence clinically significant cardiovascular , renal , hepatic , gastrointestinal , neurological , endocrine , metabolic pulmonary disease past 6 month ( determined medical history , clinical laboratory electrocardiogram [ ECG ] result , physical examination ) would increase risk associate take study medication would confound interpretation study The psychiatric diagnosis due direct pharmacological effect substance ( eg , drug abuse medication ) general medical condition ( eg , clinically notable hypothyroidism , delirium ) Meets DSMIV definition substance dependence ( except nicotine caffeine ) within 6 month prior entry Has history current symptom tardive dyskinesia ( involuntary repetitive body movement ) Has history neuroleptic malignant syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone palmitate</keyword>
	<keyword>Long-acting injectable antipsychotic medication</keyword>
</DOC>